Roy Golan - 18 Mar 2026 Form 3 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Reporting relationship: Director
Issuer ticker: NRSN
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 18 Mar 2026, 15:35:59 UTC
Prior SEC filing: 17 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Roy Golan

Key filing fact

Roy Golan filed Form 3 for NeuroSense Therapeutics Ltd. (NRSN) on 18 Mar 2026.

Key facts

This page summarizes Roy Golan's Form 3 filing for NeuroSense Therapeutics Ltd. (NRSN).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Mar 2026, 15:35.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001999257 Primary reporting owner

Golan Roy

Relationship: Director
Address: C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL
Signature: /s/ Roy Golan
Signature date: 18 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 24,000
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 60,000
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F2

NRSN holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 76,844
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's 2018 Share Incentive Plan must be registered in the name of a trustee.

Footnote F2

These restricted shares vest on December 30, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.

Footnote F3

These restricted shares vest on January 30, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.